Investment Rating - The report does not explicitly provide an investment rating for the industry. Core Insights - Long-term follow-up (LTFU) is essential for ensuring the ongoing effectiveness and safety of cell and gene therapies (CAGTs), with monitoring required for 5 to 15 years post-treatment to track delayed side effects and maintain treatment efficacy [4][7]. - The report emphasizes the need for a patient-centered, data-rich, and adaptable operational framework to address the complexities of LTFU studies, which differ significantly from traditional clinical trials [5][21]. - The future vision includes a more efficient and scalable LTFU process, integrating advanced data analytics and patient empowerment technologies, while fostering industry collaboration and data sharing [52][55]. Summary by Sections Challenges in Executing LTFU Studies - Maintaining patient engagement over long periods (5-15 years) is challenging due to potential patient dropouts and loss of interest from researchers [8][9]. - Data collection is complicated by the need to gather information across various healthcare systems and providers, leading to fragmented data [9][10]. - The geographical distribution of patients and their transitions to local healthcare providers complicate continuous data collection [10][11]. Strategies to Overcome LTFU Challenges - IQVIA employs a patient-friendly and data-efficient approach to address LTFU challenges, focusing on optimizing compliance, data quality, and patient retention while minimizing operational burdens [18]. - The design of LTFU studies must be tailored to each therapy, considering unique mechanisms of action and long-term success indicators [19][20]. - A patient-centered design approach is crucial, aligning research with the real-life experiences of patients post-treatment [20][21]. Future Vision for LTFU - The report envisions a seamless integration of LTFU into treatment development and post-market care, supported by collaborative frameworks and advanced data analytics [52][55]. - The potential for adaptive study designs that can evolve with changing scientific knowledge, regulatory frameworks, and technological tools is highlighted [47][48]. - The integration of LTFU with routine patient care is anticipated, reducing the distinction between research and healthcare [57][58]. Regulatory Leadership and Advocacy - IQVIA collaborates with regulatory bodies to shape industry standards for decentralized trial designs, registry integration, and data governance, promoting a patient-centered approach to LTFU [62].